tbuckley/cabot-search huggingface dataset:
Drug Interactions-A Problem
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain
Authors: Robert A. Mactier, Timothy S. Sprosen, Ram Gokal, Paul F. Williams, Marianne Lindbergh, Ramesh B. Naik, Ulf Wrege, Knut-Christian Grontoft, Rutger Larsson, Jonas Berglund, Anders P. Tranaeus, Dirk Faict
Journal: Kidney International (1998)
Therapeutic Talk
Authors: John P. Callan
Journal: JAMA (1980)

A decade ago during the Vietnam conflict, the initials "R&amp;R," like many other abbreviations and flip phrases of those troubled years, came into common parlance. This is an abbreviation for "rest and relaxation," a period of recuperation and making love far from the daily grind of making war. Today, as then and centuries ago, physicians are charged with the responsibility of establishing for their patients another kind of R&amp;R, in a different war. Their battle is the eternal campaign against sickness, pain, and discomfort, and their objective can be reached by mobilizing medicine's R&amp;R, reassurance and relief of suffering. The latest advances in pharmaceutical progress may be used to achieve that goal, but it can be reached with another type of medicine, one that is sometimes doubted by patient and practitioner alike. This discounted treatment is talk; a patient-physician exchange, which, when used with the same gusto as pharmaceuticals, can
Clinical Electrocardiography
Authors: Borys Surawicz
Journal: JAMA (1982)

This bulky learning package consists of two large three-ring binders (a third volume is apparently in preparation), each containing a set of seven one-hour cassette tapes, a loose-leaf illustrated text of the presentations, case studies with short bibliographies, and a self-evaluation exercise. This totals 14 hours of instruction, recited by a professional narrator who reads from the texts prepared by a faculty of ten indisputably knowledgeable experts in electrocardiography and electrophysiology. Most of the text is aimed at the beginner, although some fine points in different chapters may appeal to a more advanced clinical cardiologist. The time allotted to different topics strikes me as somewhat arbitrary and not always commensurate with the relative importance of the subject. Thus, preexcitation syndromes share an equal one-hour time with the normal ECG and myocardial infarction patterns. Much of the information is accurate and up-to-date. The diagrams tend to be instructive and the tracings
Branching gas shadows in the liver
Authors: S. B. Paster
Journal: JAMA (1976)

<h3>History</h3> A 57-year-old white woman was seen in the emergency room with a history of generalized abdominal pain and with distention of four days' duration. She suffered from obstipation, nausea, vomiting, and anorexia. There was no history of abdominal surgery, and she was not currently receiving medication. The patient was alert and in severe distress. The abdomen was grossly distended, with involuntary guarding and generalized rebound tenderness. No bowel sounds were heard. Laboratory findings were normal. <h3>Diagnosis</h3> Infarction of the small bowel with portal venous gas. The supine roentgenogram of the abdomen shows a rather pronounced gaseous distention of multiple small bowel loops (Fig 1). No intramural gas could be demonstrated in the bowel. In the right upper quadrant, there are multiple branching radiolucencies consistent with gas in the portal venous system (Fig 2). On the erect film of the chest and erect view of the abdomen (not shown), multiple
Observations on Certain Forms of Disease of the Lungs
Authors: E. L. Ormerod
Journal: BMJ (1858)

ANOTIUIIR: group of consumiptive cases has for its characteristic symptollm a violent cough meriting the nalue of tussis ferina.In somlc cases this is almost the only symptom-a loud ringing cougll Witl'1out expectoration, resulting, apparently, simply from the irritatilng presence of tubereles in the lungs.A few details of suchl cases will illustrate the cllaracters of this group better than ainy more generl dlescription.CASE V. T'ussis Fcrina: Cavity in the Lutngs.In 1850, I saw a lady, aged 28, who had been pronounced, on the muost competent authority, six years previously, to have pulmonary consumiiption.She was thin and weak, but led a life of cease- less actixity.Slhe had never hnemoptysis, and only now and then, in a miiorninlg, a little yellow expectoration.The right subelavicular region was flattened.And here was feeble in- spiration, with long expiration, loud vocal resonance, and some dullness on percussion.At the time wlhen I examinecl her chest, nio moist sound(s were audible.There could be little doubt that shie had suffered disorganiisation of the apex of the right luig, and that a cavity had forlmeed there which was now undergoin, thie process of cicatrisation.She was weak, but prominent beyond all her other symptoms was a loul barking cough, quite a tussis ferina, sounding all over the lhouse andcl ringing in every one's ears, iliore distress- ing I believe, lhowevec, and certainly mlore alarming-, to her friends than to lherself.Anid still slhe contiilues unceasingly active.An attack of con- tinued fever, with protracted irritability of the stomachl, which
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Journal: Journal of Clinical Oncology (1998)

PURPOSE To compare combination chemotherapy (CCT) versus melphalan plus prednisone (MP) as treatment for multiple myeloma. PATIENTS AND METHODS In a collaborative worldwide overview of randomized trials of CCT versus MP, individual patient data on 4,930 patients from 20 trials were analyzed, with the addition of published data on a further 1,703 patients from seven trials. The main outcome measure was mortality, with response and recurrence rates being subsidiary end points. RESULTS Taking all of the trials together, response rates were significantly higher with CCT than with MP (60.0% v 53.2%; P &lt; .00001, two-tailed). There was no evidence of any difference in mortality between CCT and MP, with a nonsignificant 1.5% reduction in death rate in favor of CCT (P = .6, two-tailed). There is heterogeneity of design between the trials, but subgroup analyses by type of CCT or by dose-intensities of CCT, of melphalan, or of prednisone did not identify any particular forms of therapy that were either clearly beneficial or clearly adverse. Similarly, analysis of the presentation features of the patients did not find any categories in which CCT differed significantly from MP in its effects on mortality; in particular, there was no evidence that poor-risk patients benefited more from CCT. CONCLUSION This overview found no difference, either overall or within any subgroup, in mortality between CCT and MP. In terms of survival, these therapeutic options, as tested in the trials considered, are approximately equivalent.
Introduction of Routine HIV Testing in Prenatal Care—Botswana, 2004
Journal: JAMA (2005)

In 2003, approximately 37% of pregnant women in Botswana (2001 population: 1.7 million; approximately 40,000 births per year) were infected with human immunodeficiency virus (HIV). Since 2001, all prenatal clinics in Botswana have offered HIV screening and interventions for prevention of mother-to-child transmission of HIV (PMTCT), which can decrease vertical transmission of HIV from 35%-40% to 5%-10%. Historically, HIV testing in Botswana has been performed after individual pretest counseling, with patients actively choosing whether to be tested (i.e., an "opt-in" approach). In 2003, 52% of pregnant women receiving prenatal care nationwide learned their HIV status. In 2004, to increase use of free national PMTCT and antiretroviral treatment (ARV) programs, Botswana began routine, noncompulsory (i.e., "opt-out") HIV screening in prenatal and other health-care settings. Concerns have been raised that routine testing in Africa might deter women from seeking prenatal care and might result in fewer women returning for their test results and HIV care after testing. To assess the early impact of routine testing on HIV-test acceptance and rates of return for care, the CDC Global AIDS Program and the PMTCT program in Botswana evaluated routine prenatal HIV testing at four clinics in Francistown, the second largest city in Botswana, where HIV prevalence has been > or =40% since 1995. This report describes the results of that assessment, which indicated that, during February-April 2004, the first 3 months of routine testing, 314 (90.5%) of 347 pregnant women were tested for HIV, compared with 381 (75.3%) of 506 women during October 2003-January 2004, the last 4 months of the opt-in testing period (p<0.001). However, many women who were tested never learned their HIV status because of logistical problems or not returning to the clinic. Substantial increases in HIV testing of pregnant women were also observed at the Francistown referral hospital and at prenatal clinics nationwide. These findings highlight the potential public health impact of routine HIV testing with rapid, same-day results for programs seeking to increase the number of persons with access to HIV-prevention and treatment services.
He Likes our Journal, but Money is Scarce.
Authors: None W. S. S.
Journal: JAMA (1896)

Millboro Springs, Va., Sept. 6, 1896. <h3>To the Editor:</h3> —I received your letter and theJournalSeptember 25; please accept my thanks for them both. After awhile (D.V.), I will become a member of theAmerican Medical Associationwhen money gets less ridiculously scarce. There is no money in rural sections now. Corn 15c. per bushel, butter 12c. per pound, sweet potatoes $1.00 in July last, when a few years back they were $7.00 per barrel. Nothing that a farmer has will sell. Send me theJournalsemi-occasionally. I enjoy the editorials; the terse and brilliant dash of the versatile pen tends to reason like the " needle to the pole," making their conclusions "solid buildings," no " castles in the air." I am like you, doctor, about that terminology of "fair culture." We were all taught in about the first lesson in our Latin grammar that "os" and "on" were Greek
Oseltamivir resistance in human seasonal influenza viruses (A/H1N1) in EU and EFTA countries: an update
Authors: None Influenza Project Team
Journal: Eurosurveillance (2008)

Following the publications in Eurosurveillance on 31 January [1,2], the European Centre for Disease Prevention and Control (ECDC), the European Influenza Surveillance Scheme (EISS), the World Health Organization (WHO) and their partners have agreed to update the data on the occurrence of resistance of influenza A/H1N1 viruses to oseltamivir appearing on the ECDC and EISS websites on a weekly basis (every Thursday afternoon). Data on the ECDC website are for European Union (EU) and European Free Trade Association (EFTA) countries. The WHO has also published a global table, which it will also refresh weekly. All these data are available through an HTML page on the ECDC web-site [3]. The European data made available through EISS and the EU DG Research-funded European Surveillance Network for Vigilance Against Viral Resistance (VIRGIL) are based on the data that have been uploaded to the EISS antiviral resistance data-base by a fixed time on a Wednesday for publication on a Thursday.
PARIS
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ABSTRACTS
Authors: STANFORD WESSLER
Journal: Circulation (1964)

In experimental cholesterol atherosclerosis of rab- bits the serum glutamic pyruvic (GPT) and glu- tamic oxaloacetic (GOT) transaminase were de- creased from the fifth to the one hundredth day of cholesterol feeding.In the early stages, GPT and GOT levels in the aorta and myocardium were raised, whereas, in the later stages, GPT levels were decreased below those in the control group.Pyridoxine increased these levels in both the se- rum and the aorta.In patients with coronarv atherosclerosis both GOT and GPT were de- creased, but increased after treatment with pyridoxine.LEPESCHKIN
Professional courtesy
Authors: Kevin Barraclough
Journal: BMJ (2005)

Your money where your mouse isThe Terri Schiavo case shows how the internet is becoming a battleground over ethical issues T here was a revolution in Central Asia, an upheaval in Lebanon, deadly shootings at a high school in Minnesota, and a disastrous explosion at a Texas oil refinery.But day after day the lead story in the august New York Times and the distinguished Washington Post was about one 41 year old woman in Florida who had been in a persistent vegetative state for 15 years-Terri Schiavo.Should US president George W Bush, a born again Christian who advocates "a culture of life," decide that she should live, or die after removal of a percutaneous gastrostomy tube providing water and nutrition?Or should Congress, the federal courts, the president's devout Catholic brother, Jeb Bush (who is governor of Florida), the Florida state courts, the Florida state legislature, her parents, or her husband make the decision?After Terri Schiavo went into a persistent vegetative state, her husband, Michael, was appointed her guardian in accordance with Florida state law.He eventually asked that her feeding tube be removed and she be allowed to die.Terri had left no "living will" or "health care proxy" (a designated person
Transient reappearance of sperm after vasectomy
Authors: S. Marshall
Journal: JAMA (1972)

Pregnancy after vasectomy may be caused by transient reappearance of sperm after the patient is believed sterile. Examination of every fourth ejaculate was carried out in 400 postvasectomy patients, eight of whom had transient reappearance of sperm. With the ever-increasing number of vasectomies being done in this country, it is important that the physician be aware of the possibility of the transient reappearance of sperm, particularly when one considers the ramifications of a postvasectomy pregnancy.
Pathways of Carbohydrate Metabolism in Normal and Neoplastic Cells
Authors: B. L. Horecker, Howard H. Hiatt
Journal: New England Journal of Medicine (1958)

Uronic Acid PathwayAn additional cyclic pathway for the metabolism of hexose phosphate has recently come to light. This pathway (Fig. 10) appears to function in the synthesis of ascorbic acid, with uronic acids as precursors. In man the operation of this pathway becomes evident only when it is blocked, as in congenital pentosuria.Glucuronic acid has been shown to serve as precursor for both ascorbic acid46 and L͇-xylulose,47 and recently some of the steps in this conversion have been elucidated.48 49 50 The reduction of glucuronic acid to L͇-gulonic acid is catalyzed by a dehydrogenase present in both plant and animal . . .
'Icebreaker' clears way for gun control efforts
Authors: C. Marwick
Journal: JAMA (1994)

AT ITS December meeting, the American Medical Association took its toughest stand yet on the issue of violence, particularly as it relates to guns, calling for restrictions on the purchase of weapons and ammunition. The House of Delegates reaffirmed its support for the Brady bill, which requires a 5-day interval between purchase and pickup of a handgun, and called for restrictions on the sale of assault weapons. These were just a few steps in the growing national momentum for gun control efforts. The Brady bill signed into law at the end of November is, in the view of antigun lobbyists, just the beginning of increased pressure for gun control laws. "We intend to push for some very aggressive gun control legislation," says Richard Aborn, president of Handgun Control Inc, one of the more assertive gun control lobbying groups in the nation's capital. "To us, the Brady bill is the political
THE EPIDEMIC OF INFLUENZA.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1382: Megakaryocyte potentiating factor as a predictive biomarker for therapies against malignant mesothelioma
Authors: Liang Cao, Yunkai Yu, Anish. Thomas, Jingli Zhang, Masanori Onda, Paul Meltzer, Raffit Hassan, Ira Pastan
Journal: Cancer Research (2019)

Abstract Objectives: Effective biomarkers for malignant mesothelioma (MM) are needed for clinical management and the development of cell surface mesothelin-targeted therapies. We evaluated serum megakaryocyte potentiating factor (MPF) as a biomarker predictive of clinical outcome in MM patients, for patient monitoring, and for developing mesothelin-targeted therapies. Patients and Methods: Serial serum samples from MM patients in two clinical trials of an anti-mesothelin immunotoxin were tested for serum MPF. For the purpose, we developed a new MPF assay and conducted both analytical and clinical validation. Correlative studies were performed to determine the test effectiveness in treatment monitoring and outcome prediction. MPF was further evaluated for an association with response to an anti-mesothelin therapy and for disease monitoring. Results: Our data showed that in MM patients, elevated serum MPF is a predictor of poor survival with a hazard ratio (HR) = 2.46 (Log Rank P = 0.003; n = 95). In refractory MM patients, elevated MPF is a strong predictor of poor outcome with a HR = 6.12 (Log Rank P = 0.0007; n = 57). There was a significant reduction of serum MPF in patients with elevated baseline and radiological response, with an average change from -52% to -78% after 1 to 6 cycles. Using a -50% change as the cutoff, MM patients with a positive MPF-response had significantly improved progression-free survival (PFS) (P &amp;lt; 0.0001), with median extended from 1.9 to 11.3 months. These MPF-response patients further exhibited improved overall survival (OS) (P = 0.004), with median extended from 8.8 to 22.3 months. In refractory MM patients, there was an association between elevated pre-treatment serum MPF and radiological response to an experimental anti-mesothelin therapy (P = 0.033). Furthermore, in these response patients, serum MPF was monitored between 32.2 and 63.8 months and found to reflect the response and disease progression. Conclusion: In MM patients, elevated MPF was observed in 2/3rd of the patients and is a predictor for poor survival, throughout the course of the disease. Following systemic therapies, a &amp;gt; -50% reduction in MPF was associated with improved clinical outcome, both PFS and OS. An elevated baseline serum MPF may be a predictor of response to an experimental anti-mesothelin therapy in refractory MM patients, however, the finding needs to be confirmed in a larger study. Citation Format: Liang Cao, Yunkai Yu, Anish. Thomas, Jingli Zhang, Masanori Onda, Paul Meltzer, Raffit Hassan, Ira Pastan. Megakaryocyte potentiating factor as a predictive biomarker for therapies against malignant mesothelioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1382.
WHERE IGNORANCE IS BLISS, 'TIS FOLLY TO BE WISE.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal